# COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF

> **NCT02582190** · PHASE3 · WITHDRAWN · sponsor: **Elpen Pharmaceutical Co. Inc.**

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Colchicine group

## Key facts

- **NCT ID:** NCT02582190
- **Lead sponsor:** Elpen Pharmaceutical Co. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-02
- **Primary completion:** 2018-09-02
- **Final completion:** 2018-09-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigational Medicinal Product Supplies
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582190, "COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02582190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*